CCL2 and neoplasm: For LUAD tumor cells with the ability to metastasize to the pleura and foster a malignant pleural effusion (MPE), it has been shown that the determining factor is the presence of KRAS activating mutations, which favor the production of CCL2 by the tumor cells.